- Home
- BORR vs SYRE Comparison
BORR vs SYRE Comparison
Compare BORR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BORR | SYRE |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BORR | SYRE |
|---|---|---|
| Price | $3.94 | $33.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.75 | ★ $55.50 |
| AVG Volume (30 Days) | ★ 5.2M | 729.3K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,024,500,000.00 | N/A |
| Revenue This Year | $1.03 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $1.55 | $10.91 |
| 52 Week High | $4.48 | $35.31 |
Technical Indicators
Market Signals| Indicator | BORR | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 61.71 | 69.75 |
| Support Level | $3.25 | $33.51 |
| Resistance Level | $3.34 | $35.31 |
| Average True Range (ATR) | 0.24 | 1.87 |
| MACD | 0.06 | 0.31 |
| Stochastic Oscillator | 62.90 | 84.11 |
Price Performance
Historical ComparisonAbout BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.